JPY 163.0
(-1.81%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 91.49 Million JPY | -73.12% |
2022 | 340.41 Million JPY | 297.14% |
2021 | 85.71 Million JPY | 12.96% |
2020 | 75.88 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 107.21 Million JPY | 17.18% |
2024 Q2 | 81.29 Million JPY | -24.18% |
2023 Q3 | 201.75 Million JPY | 1.57% |
2023 FY | 91.49 Million JPY | -73.12% |
2023 Q1 | 202.06 Million JPY | -40.64% |
2023 Q2 | 198.64 Million JPY | -1.69% |
2023 Q4 | 91.49 Million JPY | -54.65% |
2022 Q4 | 340.41 Million JPY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
KOHJIN BIO CO LTD | 3.24 Billion JPY | 97.182% |
PRISM BioLab Co.,LTD | 63.41 Million JPY | -44.287% |
GNI Group Ltd. | 26.34 Billion JPY | 99.653% |
Linical Co., Ltd. | 10.3 Billion JPY | 99.112% |
Trans Genic Inc. | 3.81 Billion JPY | 97.6% |
MEDINET Co., Ltd. | 590.2 Million JPY | 84.498% |
Soiken Holdings Inc. | 697.02 Million JPY | 86.874% |
Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 96.971% |
AnGes, Inc. | 2.78 Billion JPY | 96.72% |
OncoTherapy Science, Inc. | 513.6 Million JPY | 82.186% |
Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.899% |
Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 74.101% |
NanoCarrier Co., Ltd. | 1.64 Billion JPY | 94.455% |
Carna Biosciences, Inc. | 472.35 Million JPY | 80.63% |
CanBas Co., Ltd. | 91.98 Million JPY | 0.537% |
D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 91.634% |
RaQualia Pharma Inc. | 809.83 Million JPY | 88.702% |
Chiome Bioscience Inc. | 593.73 Million JPY | 84.59% |
Kidswell Bio Corporation | 4.25 Billion JPY | 97.849% |
PeptiDream Inc. | 29.11 Billion JPY | 99.686% |
Oncolys BioPharma Inc. | 566.5 Million JPY | 83.849% |
Ribomic Inc. | 155.8 Million JPY | 41.278% |
SanBio Company Limited | 2.25 Billion JPY | 95.942% |
Healios K.K. | 11.28 Billion JPY | 99.189% |
BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 63.587% |
Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 75.205% |
Delta-Fly Pharma, Inc. | 241.49 Million JPY | 62.114% |
StemRIM | 187 Million JPY | 51.073% |
CellSource Co., Ltd. | 677.73 Million JPY | 86.5% |
FunPep Company Limited | 189.32 Million JPY | 51.673% |
Kringle Pharma, Inc. | 596.95 Million JPY | 84.673% |
Stella Pharma Corporation | 1.44 Billion JPY | 93.662% |
TMS Co., Ltd. | 97.68 Million JPY | 6.342% |
Cuorips Inc. | 200.96 Million JPY | 54.472% |
K Pharma,Inc. | 209.13 Million JPY | 56.251% |
Takara Bio Inc. | 11.42 Billion JPY | 99.199% |
ReproCELL Incorporated | 741.03 Million JPY | 87.653% |
PhoenixBio Co., Ltd. | 917.71 Million JPY | 90.03% |
StemCell Institute Inc. | 3.85 Billion JPY | 97.624% |
Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 89.928% |
CellSeed Inc. | 301.04 Million JPY | 69.608% |